Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7126 to 7140 of 8212 results

  1. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued Reference number: GID-TA10590

    Technology appraisal guidance
    Discontinued

  2. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

    Technology appraisal guidance
    Discontinued

  3. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

    In development Reference number: GID-TA10598 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Omburtamab for treating relapsed neuroblastoma [ID1664]

    In development Reference number: GID-TA10608 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued Reference number: GID-TA10609

    Technology appraisal guidance
    Discontinued

  7. Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

    Discontinued Reference number: GID-TA10616

    Technology appraisal guidance
    Discontinued

  8. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued Reference number: GID-TA10617

    Technology appraisal guidance
    Discontinued

  9. Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

    Discontinued Reference number: GID-TA10625

    Technology appraisal guidance
    Discontinued

  10. Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]

    Discontinued Reference number: GID-TA10627

    Technology appraisal guidance
    Discontinued

  11. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued Reference number: GID-TA10628

    Technology appraisal guidance
    Discontinued

  12. Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

    Discontinued Reference number: GID-TA10631

    Technology appraisal guidance
    Discontinued

  13. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued Reference number: GID-TA10863

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued Reference number: GID-TA10766

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued Reference number: GID-TA11004

    Technology appraisal guidance
    Discontinued